Drug Profile
ORM 2110
Alternative Names: 212-Pb-Targeted-Alpha-Emmitter-Therapy; 212Pb-AR-RMX; 212Pb-octreotate analog; AlphaMedix; Lead-212 radionuclide; ORM-2110; Pb212-octreotide analog; ²¹²Pb-DOTAMTATELatest Information Update: 20 Feb 2024
Price :
$50
*
At a glance
- Originator AREVA Med; RadioMedix
- Developer Orano Med; RadioMedix
- Class Antineoplastics; Drug conjugates; Peptides; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neuroendocrine tumours
Most Recent Events
- 12 Feb 2024 ORM 2110 receives Breakthrough Therapy status for Neuroendocrine tumours (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA
- 12 Feb 2024 Updated efficacy data from a phase I trial in Neuroendocrine tumours released by RadioMedix
- 16 May 2023 RadioMedix completes enrolment in its phase II trial for Neuroendocrine tumours (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in the US (NCT05153772)